Amarin Corp Plc (AMRN)

[ziploc_1]

In 2013, the FDA demanded a large multiyear clinical event trial before they would approve Vascepa for Rx of CVD(i.e. the Reduce-It study)....Amarin did this study on Vascepa at it's own huge expense and achieved success...and eventually got awarded approval by the FDA.

Generic Vascepa does not have the same patented gelatin capsule as does Vascepa...Yet no event studies were demanded of gV by the FDA like they were demanded of Vascepa...Does this mean that the FDA assumed that the Vascepa capsule made no difference?

Dr. Preston Mason has been doing research on the positive effect on the EPA by the Vacepa patented capsule ....I have been taking Vascepa in preference to gV because of this capsule....Unless we hear some information from Dr. Mason on his research, I/we must assume that the patented capsule does, in fact, make no difference to the amount and/or quality of the EPA in Vascepa.